The Food and Drug Administration (FDA) on Tuesday gave emergency use authorization for a new combination antibody drug from Eli Lilly that the company says can treat mild and moderate cases of the coronavirus.
The authorization from the FDA is for a treatment that uses both bamlanivimab and etesevimab. It can be used to treat mild or moderate COVID-19 cases in adults and pediatric patients who test positive for the virus and who are at high risk for progressing to severe illnesses. The treatment cannot be used for patients who are hospitalized or require oxygen therapy from the coronavirus.
The FDA had previously authorized a treatment from Eli Lilly that just used bamlanivimab.
The new authorization permits the federal government to distribute the treatment to state and territorial health departments to give to certain facilities.
Read more at The Hill.
{Matzav.com}
